Search - tctmd.com

Displaying 21 - 40 of 100

Sort: Relevancy | Date

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Industry News

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

October 30, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

News Industry News

Medinol Announces Outstanding Results in a Randomized Trial of a New Drug Eluting Stent

May 17, 2016

News Daily News

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Michael O'Riordan

March 30, 2016

Advertisement

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Medinol Announces Outstanding Results in a Randomized Trial of a New Drug Eluting Stent

Absorb BVS: Safety, Efficacy, and Stent Thrombosis Tackled in Two New Analyses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content